FAQ
Who is eligible to apply?
Researchers from universities, other academic research institutes and start-up companies from all over the world.
What types of grants are offered?
We intend to offer the following different types of grants depending on the specifics of the target and its development phase.
For what indications are grants offered?
Grants are offered for the following indications:
Will the information provided be considered confidential?
No, the information provided will not be considered confidential. Information provided has to be sufficient to allow a first evaluation of the proposal. If you have further data that you are only willing to disclose subject to the execution of a Confidential Disclosure Agreement (CDA), please indicate this in the abstract. In case your application is considered for further evaluation, we may contact you to discuss a CDA.
Who will review the proposals?
The proposals will be reviewed by experts from Bayer Schering Pharma.
What should the proposal cover?
The proposal should include a detailed description of the target proposed and further research plans (as requested in the submission form). The information provided must be sufficient to allow an initial evaluation of the proposal. Please note that only non-confidential information should be provided. Our aim is to combine your scientific expertise with our drug-development know-how to generate drugs for novel targets in an efficient and straightforward approach.
Deadlines for the application?
The next deadline for submission is September 30, 2010.
What is regarded as a target?
We define a “drugable” target as a gene/protein that is amenable to modulation by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in the disease by relevant in vitro or in vivo models.
The current call for proposals is limited to the mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets. Examples of successful drugable targets have been found in particular in the following target classes: enzymes (e.g. kinases, proteases), transmembrane proteins, GPCRs and other receptors, secreted proteins, and growth factors.
Can I submit a proposal on behalf of a group?
Yes, you can submit a proposal on behalf of your group. However, please indicate your collaborators/coworkers in the respective field.
Do I have to apply for a specific grant?
No, it is not necessary to specify the grant type. However, it would help us in our grant allocation if you could indicate your research plans on the proposed target.
Do the publications attached have to originate from myself/my research group?
No, please attach the most relevant publications describing the target and its functional relevance for disease.
Researchers from universities, other academic research institutes and start-up companies from all over the world.
What types of grants are offered?
We intend to offer the following different types of grants depending on the specifics of the target and its development phase.
- Support Grants (€5,000-€10,000) to further advance research on targets that are at a very early stage of discovery
- Focus Grants (€10,000-€125,000) for more mature ideas, e.g. to address specific aspects of a target as a first step toward transferring it to the drug-discovery process.
- Collaborative Grants (€50,000-€250,000) to move the target into the drug-discovery process in a substantial joint effort.
For what indications are grants offered?
Grants are offered for the following indications:
- Oncology
focusing on anti-angiogenic, anti-tumor and selective anti-proliferative therapies for solid tumors. - Cardiology
focusing on novel approaches to the care of chronic and/or acute pulmonary hypertension, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, disseminated intravascular coagulation, acute lung injury/adult respiratory distress syndrome, and cardioprotection. - Gynecology
focusing on novel treatment options for endometriosis (adenomyosis uteri/endometriosis interna) and uterine fibroids (uterine leiomyoma). - In vivo Imaging
focusing on oncology (early diagnosis and staging, early therapy response, predictive stratification of patients) and CNS (Alzheimer’s disease, other forms of dementia, neuroinflammation), using positron emission tomography (PET) as modality.
Will the information provided be considered confidential?
No, the information provided will not be considered confidential. Information provided has to be sufficient to allow a first evaluation of the proposal. If you have further data that you are only willing to disclose subject to the execution of a Confidential Disclosure Agreement (CDA), please indicate this in the abstract. In case your application is considered for further evaluation, we may contact you to discuss a CDA.
Who will review the proposals?
The proposals will be reviewed by experts from Bayer Schering Pharma.
What should the proposal cover?
The proposal should include a detailed description of the target proposed and further research plans (as requested in the submission form). The information provided must be sufficient to allow an initial evaluation of the proposal. Please note that only non-confidential information should be provided. Our aim is to combine your scientific expertise with our drug-development know-how to generate drugs for novel targets in an efficient and straightforward approach.
Deadlines for the application?
The next deadline for submission is September 30, 2010.
What is regarded as a target?
We define a “drugable” target as a gene/protein that is amenable to modulation by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in the disease by relevant in vitro or in vivo models.
The current call for proposals is limited to the mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets. Examples of successful drugable targets have been found in particular in the following target classes: enzymes (e.g. kinases, proteases), transmembrane proteins, GPCRs and other receptors, secreted proteins, and growth factors.
Can I submit a proposal on behalf of a group?
Yes, you can submit a proposal on behalf of your group. However, please indicate your collaborators/coworkers in the respective field.
Do I have to apply for a specific grant?
No, it is not necessary to specify the grant type. However, it would help us in our grant allocation if you could indicate your research plans on the proposed target.
Do the publications attached have to originate from myself/my research group?
No, please attach the most relevant publications describing the target and its functional relevance for disease.